Structure Therapeutics (NASDAQ:GPCR) Stock Rating Lowered by Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other brokerages have also weighed in on GPCR. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. JPMorgan Chase & Co. increased their price objective on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, January 22nd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, January 6th. Citizens Jmp boosted their target price on shares of Structure Therapeutics from $87.00 to $120.00 and gave the stock a “market outperform” rating in a research report on Friday, December 12th. Finally, Jefferies Financial Group set a $125.00 price target on shares of Structure Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.45.

Structure Therapeutics Stock Up 1.5%

GPCR stock opened at $88.45 on Friday. The company has a 50 day moving average of $66.22 and a two-hundred day moving average of $38.93. The company has a market cap of $5.37 billion, a price-to-earnings ratio of -72.50 and a beta of -2.05. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, research analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Ameriprise Financial Inc. raised its holdings in Structure Therapeutics by 7.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after acquiring an additional 106,389 shares in the last quarter. Casdin Capital LLC raised its stake in shares of Structure Therapeutics by 26.9% in the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after purchasing an additional 330,000 shares in the last quarter. Millennium Management LLC lifted its position in Structure Therapeutics by 4.5% in the third quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock worth $35,687,000 after purchasing an additional 54,496 shares during the period. Orbimed Advisors LLC boosted its stake in Structure Therapeutics by 49.5% during the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after buying an additional 397,272 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Structure Therapeutics by 0.5% in the 3rd quarter. Franklin Resources Inc. now owns 745,734 shares of the company’s stock valued at $20,881,000 after buying an additional 3,951 shares during the period. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.